Impax Laboratories Inc.
30831 Huntwood Avenue
Hayward,
CA 94544
United States - Map
Phone: 510-476-2000
Fax: 510-471-3200
Web Site: http://www.impaxlabs.com
| Impax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical. The Global Pharmaceuticals division develops, formulates, manufactures, and sells controlled release and specialty generic pharmaceutical products. This division offers generic prescription products directly to wholesalers and large retail drug chains; and generic over-the-counter and generic prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimers disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinsons disease, and schizophrenia. As of March 10, 2009, the company marketed 70 generic pharmaceuticals representing dosage variations of 24 different pharmaceutical compounds through its Global Pharmaceuticals division, as well as 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements partners. Impax Laboratories markets and sells its generic pharmaceutical prescription drug products in the continental United States of America and the Commonwealth of Puerto Rico. It has alliance agreements with Teva Pharmaceutical Industries, Ltd.; Wyeth; Schering-Plough Corporation; and DAVA Pharmaceuticals, Inc. The company was founded in 1993 and is headquartered in Hayward, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Larry Hsu Ph.D., 61
Chief Exec. Officer, Pres |
N/A
| N/A | Mr. Arthur A. Koch Jr., 56
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Corp. Sec. |
N/A
| N/A | Mr. Charles V. Hildenbrand , 58
Sr. VP of Operations |
N/A
| N/A | Mr. Michael J. Nestor , 56
Divisional Pres of Impax Pharmaceuticals |
$
521.00K | N/A | Mr. Christopher Mengler R.Ph., 47
Pres of Global Pharmaceuticals Division |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.52% Nasdaq 0.00%
Profile
